Subretinal Gene Therapy Drug AGTC-501 for XLRP Phase 1/2 Multicenter Study (HORIZON): 24-Month Safety and Efficacy Results
Titel:
Subretinal Gene Therapy Drug AGTC-501 for XLRP Phase 1/2 Multicenter Study (HORIZON): 24-Month Safety and Efficacy Results
Auteur:
Yang, Paul Birch, David Lauer, Andreas Sisk, Robert Anand, Rajiv Pennesi, Mark E. Iannaccone, Alessandro Yaghy, Antonio Scaria, Abraham Jung, Jung Ah Curtiss, Darin Waheed, Nadia K.